The Molecular Biomarker Revolution in Metastatic NSCLC
During this recorded 2022 ASCP Annual Meeting session, multidisciplinary faculty will discuss the science and latest evidence on emerging biomarkers, resistance mutations, immuno-oncology (I-O) resistance mechanisms, and I-O treatment options (e.g., combination therapy involving CTLA-4 inhibitors) in metastatic NSCLC. In addition, they will address how to integrate next generation sequencing (NGS) into your biomarker testing workflows and optimize its use for patients. Finally, they will share best practices in biomarker testing, reporting, and communication to help pathologists and laboratory professionals guide medical oncologists and other team members in the appropriate diagnosis, testing, and treatment for patients. The activity offers 1.0 CME/CMLE credit. The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. Learning ObjectivesUpon completion of this activity, you should be able to:· Describe ongoing investigational efforts regarding emerging biomarkers in metastatic NSCLC · Utilize NGS to identify current and emerging biomarkers to predict response to personalized therapies for patients with metastatic NSCLC · Employ strategies for optimizing workflows and turnaround times for NGS · Discuss the science behind resistance mechanisms in patients with metastatic NSCLC · Recognize the use of emerging I-O combination therapies and potential biomarkers in patients with metastatic NSCLC · Develop ways to improve communication among pathologists, oncologists, and other members of the multidisciplinary lung cancer care team FacultyDiana N. Ionescu MD, FRCPC, FCAP Consultant Pathologist and Medical Lead Anatomical Pathology Medical Director BC Cervical Cancer Screening Laboratory Medical Director Clinical Trials, BC Cancer Laboratories Clinical Professor of Pathology, University of British Columbia Doru Paul, MD, PhDAttending Physician, Division of Hematology and Medical Oncology Weill Cornell and New York Presbyterian Hospital Faculty DisclosuresThe following Panel/Faculty members have relevant financial relationships to disclose: | Faculty Member | Ineligible Company | For what role? | Diana Ionescu, MD | AstraZeneca, Bayer, BMS, Merck, Pfizer, Roche | Consultant, Consultant, Consultant, Consultant, Consultant, Consultant Dr. Paul has no relevant financial relationships to disclose All of the relevant financial relationships listed for these individuals have been mitigated Commercial SupportFunded by an independent educational grant from AstraZeneca Pharmaceuticals